Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hepatitis A vaccine AVAXIM 80U · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Hepatitis A vaccine AVAXIM 80U | BIOLOGICAL | 0.5 mL, Intramuscular |
| Hepatitis A vaccine (HAVRIX 720) | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria : Inclusion criteria to be checked at the screening visit (SC): 1. Toddlers, children and adolescents: Sub-Group 1: from 12 months to 3 years of age on the day of inclusion Sub-Group 2: from 4 to 6 years of age on the day of inclusion Sub-Group 3: from 7 to 9 years o...
Hepatitis A vaccine AVAXIM 80U is used for the prevention of Hepatitis A infection. It is an investigational vaccine being developed by Sanofi for use in pediatric populations, specifically studied in children as young as 12 months of age.
Hepatitis A vaccine AVAXIM 80U is developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The vaccine is being studied for the prevention of Hepatitis A.
Hepatitis A vaccine AVAXIM 80U is in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved for public use and is still undergoing clinical trials to evaluate its safety and immunogenicity.
Hepatitis A vaccine AVAXIM 80U has been studied in a Phase 3 clinical trial with the identifier NCT00483470. This completed trial, titled 'Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose,' enrolled 720 participants in China to evaluate the vaccine's safety and immune response.
Hepatitis A vaccine AVAXIM 80U is classified as a monoclonal antibody modality, though it is being developed as a vaccine for the prevention of Hepatitis A. It is currently in Phase 3 clinical trials and is not yet approved for use.